Endocrine Abstracts

Introduction: Pregnancy results in a significant change in pituitary gland size and function.Due to this physiological adaptation, management of pituitary adenomas during pregnancy represents a particularly complex challenge. Aim of this study was to focus on a single referral institution experience with special attention to this subgroup of patients: pregnant woman affected by pituitary adenoma.Materials and methods: This is a des...

Introduction: Pasireotide long acting release (LAR) is approved for second line treatment of acromegaly. We present 3 patients with aggressive acromegaly treated with a personalized de-escalation approach.Case 1: A 61-year-old female affected by acromegaly reisistant on first-line SSAs. In 2015 therapy was switched to pasireotide LAR 60 mg every 28 days. After two years, the IGF-I level touched the lower age range and therapy was downscaled to pasireotid...

Background: Cushing’s disease, the most common cause of endogenous Cushing’s syndrome, is caused by a pituitary tumor secreting adrenocorticotropic hormone (ACTH). Careful selection of treatment and management of the disease and associated comorbidities are necessary to improve prognosis.Case Presentation: A 32-year-old patient came to our observation for appearance of weight gain with abdominal obesity, hirsutism and amenorrhea. On suspicion o...

Introduction: Non functioning pituitary adenomas (NFPAs) are the most common type of pituitary tumors and are often invasive, resulting in high relapse rates. The post-surgical treatment for NFPAs remains a debated issue and include radiation therapy and additional surgery. Several clinical studies have demonstrated that dopaminergic and somatostatin receptors (SSTRs) are widely expressed in NFPAs. Furthermore, recent studies have shown the potential effectiveness of somatosta...

Teratomas comprise 0.5% of all intracranial tumors. 15 cases of sellar teratoma have been described in the last 24 years (yrs). A 29-yrs female pan-hypopituitaric patient (pt) was admitted to our Pituitary Unit. At 6-yrs age, for polyuria and growth delay, an endocrine evaluation revealed diabetes insipidus and hypopituitarism. Cranial contrasted-MRI (cc-MRI) showed pituitary stalk thickening and a low intensity suprasellar lesion. Histological examination (HE) was suggestive ...

Background: Achievement of blood pressure (BP) control is an important target in type 2 diabetic patients (T2DM) to prevent microvascular and macrovascular complication. T2DM patients are characterized by endothelial dysfunction, which represents a key mechanism for the development of atherosclerotic disease.Aim: The aim of this study is to evaluate the effect of a nutritional and dietary counseling on BP control and endothelial dysfunction in T2DM.<...

Background: Anorexia nervosa (AN) is prevalent in modern societies, this pathogenesis is not yet well understood.Aim: The aim of this study is to evaluate circulating levels of adiponectine (Apn) and the relationship between these levels and anthropometric and metabolic parameters.Methods: The study included 40 women, 20 with AN (BMI 15.7±2.1 kg/m2, age 30.2±10.5 years), 12 restricter (BMI 14.9±1.6 kg/m<su...

Insulin sensitivity in GHD patients tends to decrease with age and variations in body composition. Several indices of insulin sensitivity have been considered and among these HOMA, ISI and QUICKI are based on mathematical calculations taking into account glucose and/or insulin levels either in basal conditions or after OGTT. Aim of present study was to validate the different indices in a population of pre-pubertal GHD children (n=66) by ROC curve analysis. All patients ...

Acromegalic osteopathy is an emerging complication of chronic GH excess characterized by increase in bone turnover, deterioration in bone microarchitecture and high risk of vertebral fractures (VFs). Medical therapies may exert direct effects on peripheral targets leading to improvement of clinical outcomes regardless of biochemical control of acromegaly. In this longitudinal study, we compared the effects pegvisomant (PegV) and somatostatin receptor ligands (SRLs) on VF risk ...

Pasireotide, a multireceptor-targeted somatostatin analogue, was approved for the treatment of acromegaly, after being studied in two large, randomised, multi-center clinical trials. We reported the history of a 76 years old man affected by acromegaly, treated with Pasireotide long acting release (LAR) as first line therapy. Acromegaly was diagnosed in 2009, as the result of endocrinological investigation suggested by altered facial appearance and macroglossia. Hormonal assays...